Roche/Ionis Pharmaceuticals Inc. and Active Biotech AB/Teva Pharmaceutical Industries Ltd.are both due to report high-impacting clinical trial data in the coming months for drugs targeting the cause of Huntington's disease.
Roche and Ionis will published top-line Phase II data soon for potential antisense drug IONIS-HTTRx; meanwhile, Active Biotech and Teva will present Phase II
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?